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i.org/1disease remains controversial. The aim of this study was to evaluate the impact of early
coronary revascularization on long-term outcomes (>10 years) after an ischemic dobut-
amine stress echocardiography (DSE) in patients with known or suspected coronary artery
disease. Patients without stress-induced ischemia on DSE and those who underwent late
coronary revascularization (>90 days after DSE) were excluded. The ﬁnal study cohort
consisted of 905 patients. A DSE with a peak wall motion score index of 1.1 to 1.7 was
considered mild to moderately abnormal (n [ 460), and >1.7 was markedly abnormal
(n [ 445). End points were all-cause and cardiac mortality. The impact of early coronary
revascularization on outcomes was assessed using Kaplan-Meier survival analysis and
Cox’s proportional hazard regression models. Early coronary revascularization was per-
formed in 222 patients (percutaneous coronary intervention in 113 [51%] and coronary
artery bypass grafting in 109 patients [49%]). During a median follow-up time of 10 years
(range 8 to 15), 474 deaths (52%) occurred, of which were 241 (51%) due to cardiac causes.
Kaplan-Meier survival curves showed that both in patients with a markedly abnormal DSE
and a mild-to-moderately abnormal DSE, early revascularization was associated with better
long-term outcomes. Multivariable analyses revealed that early revascularization had a
beneﬁcial effect on all-cause mortality (hazard ratio 0.60, 95% conﬁdence interval 0.46 to
0.79) and cardiac mortality (hazard ratio 0.49, 95% conﬁdence interval 0.34 to 0.72). In
conclusion, early coronary revascularization has a beneﬁcial impact on long-term outcomes
in patients with myocardial ischemia on DSE. Early coronary revascularization was
associated with better outcomes not only in patients with a markedly abnormal DSE
but also in those with a mild to moderately abnormal DSE.  2016 The Author(s).
Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/). (Am J Cardiol 2016;118:635e640)Coronary artery disease (CAD) remains the leading cause
of mortality worldwide.1 Medical therapy and revasculari-
zation (either percutaneous coronary intervention [PCI] or
coronary artery bypass grafting [CABG]) are both valuable
treatment options of patients with stable CAD.2,3 Major
advances in medical therapy and invasive coronary pro-
cedures have contributed to improved outcomes. In patients
with acute coronary syndrome, it has been shown that cor-
onary revascularization substantially reduces mortality.4
However, the role of early coronary revascularization in
the management of stable CAD remains controversial. The
Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evalution (COURAGE) trial, among pa-
tients with stable ischemic heart disease, demonstrated no
difference in long-term mortality rates with medical therapyf Cardiology, Thoraxcenter, Erasmus Medical Center,
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0.1016/j.amjcard.2016.06.026and PCI compared with medical therapy alone.5 Information
on the impact of coronary revascularization on long-term
outcome in patients with myocardial ischemia at dobut-
amine stress echocardiography (DSE) is scarce. The follow-
up period in previous studies was on average 3 years.6,7
Accordingly, the objectives of the present study were
twofold: (1) to evaluate the impact of early coronary
revascularization on long-term (>10 years) mortality after
an ischemic DSE and (2) to evaluate whether the amount
of ischemia determines the prognostic beneﬁt of
revascularization.
Methods
The study population consisted of 3,922 consecutive
patients with known or suspected CAD who underwent DSE
from January 1990 to January 2003. Only patients with
stress-induced ischemia on DSE were included (n ¼ 1,191).
Early coronary revascularization was deﬁned as PCI or
CABG 90 days after DSE. Patients who underwent late
revascularization (deﬁned as >90 days after DSE) were
excluded (n ¼ 286). The reason for this exclusion was based
on the primary goal of the present study, that is, to evaluate
the impact of early revascularization (90 days after DSE).ccess article www.ajconline.org
636 The American Journal of Cardiology (www.ajconline.org)The decision to revascularization was made on clinical
grounds. The ﬁnal study cohort consisted of 905 patients.
The test was requested for diagnostic reasons in 517 patients
(57%), for preoperative cardiac risk assessment in 211
(23%), or for evaluation of viable myocardium in 177 (20%)
with left ventricular dysfunction. Clinical data were
collected at the time of DSE. Hypercholesterolemia was
deﬁned as total cholesterol >200 mg/dl or use of lipid-
lowering medications. Hypertension was deﬁned as
systolic blood pressure 140 mm Hg, diastolic blood
pressure 90 mm Hg, or use of antihypertensive medica-
tion. Diabetes was deﬁned in the presence of fasting blood
glucose 140 mg/dl or requirement for insulin or oral hy-
poglycemic agents. Heart failure was deﬁned according to
the New York Heart Association classiﬁcation.8 This study
was not subject to the Dutch Medical Research Involving
Human Subjects Act. Therefore, approval from the local
research ethics committee to conduct this prospective
follow-up study was not required at the time of enrollment.
The study was conducted according to the Declaration of
Helsinki.9 All patients consented participation in this study.
After baseline echocardiography, dobutamine was
infused at a starting dose of 5 mg/kg/min for 3 minutes,
followed by 10 mg/kg/min for 3 minutes (low-dose stage).
The dobutamine dose was increased by 10 mg/kg/min every
3 minutes, up to a maximum dose of 40 mg/kg/min. Atro-
pine (up to 1 mg) was administered intravenously at the end
of the last stage if the target heart rate was not achieved. End
points of the test were an achievement of the target heart rate
(85% of the maximal heart rate predicted for age), the
maximal dose of dobutamine and atropine, >2 mV
downsloping ST-segment depression measured 80 ms from
the J point compared with baseline, hypertension (blood
pressure >240/120 mm Hg), a decrease in systolic blood
pressure of >40 mm Hg, and signiﬁcant arrhythmias.
Typical angina during dobutamine stress testing was deﬁned
as substernal chest discomfort provoked by dobutamine
stress and relieved by withdrawing dobutamine.
Echocardiographic images (2 dimensional, using stan-
dard views) were acquired at rest and continuously during
the test and recovery. The interpretation of images was
performed by 2 independent blinded observers. In case of
disagreement, a third observer also interpreted the images.
In our laboratory, the inter- and intraobserver agreement for
DSE assessments are 92% and 94%, respectively.10
Regional wall motion and systolic wall thickening were
scored using a standard 16-segment left ventricular model.
Each segment was scored using a 5-point scale as follows:
1 ¼ normal, 2 ¼ mild hypokinesis, 3 ¼ severe hypokinesis,
4 ¼ akinesis, and 5 ¼ dyskinesis. Ischemia was deﬁned as
new or worsened wall motion abnormalities during stress,
which is indicated by an increase of 1 grade in 1
segment of the wall motion score. A biphasic response in an
akinetic or severely hypokinetic segment was considered as
an ischemic response. When akinetic segments at rest
became dyskinetic during stress, this was not considered as
ischemia.11 DSE results were deﬁned as abnormal if there
was ischemia during stress or ﬁxed wall motion abnormal-
ities. The wall motion score index (WMSI) was calculated
by dividing the sum of segment scores by 16. The WMSI
was obtained at rest and at peak stress. A DSE with a peakWMSI of 1.1 to 1.7 was considered mild to moderately
abnormal and >1.7 was markedly abnormal.12
Outcome data were obtained by a questionnaire, evalu-
ation of hospital records, contacting the patient’s general
practitioner, and/or review of civil registries. The online
municipal civil registry was used to determine the patient’s
present survival status. The date of response was used to
calculate follow-up time. The end points considered were
all-cause and cardiac mortality. Causes of death were
obtained from the Central Bureau of Statistics Netherlands.
A death caused by acute MI, signiﬁcant arrhythmias,
refractory heart failure, or sudden death without other
explanation was deﬁned as cardiac mortality.
Continuous data were presented as mean  SD and were
compared using the Student t test. Categorical data were
presented as percentages and were compared using the chi-
square test. Correlation between continuous variables was
estimated with Pearson’s correlation coefﬁcient. Survival
curves were generated using the Kaplan-Meier method to
assess the probability of (event free) survival and were
compared using the log-rank test. The impact of early cor-
onary revascularization on survival was investigated using
univariable and multivariable Cox’s proportional hazard
regression models. The multivariable model was performed
using known prognostic factors, including clinical charac-
teristics and DSE results. The risk of a variable was
expressed as a hazard ratio with a corresponding 95%
conﬁdence interval; p <0.05 was considered statistically
signiﬁcant. All analyses were performed with IBM SPSS
statistical software, version 22, Armonk, New York.
Results
The clinical characteristics of the 905 patients with
myocardial ischemia on DSE are presented in Table 1. The
mean age was 61 years, and the majority of the patients were
men (76%). During the dobutamine stress test, heart rate
increased from a mean of 70  13 beats/min to 128  19
beats/min (p <0.001), whereas overall systolic blood pres-
sure did not signiﬁcantly change (132  25 mm Hg at rest
and 132  29 mm Hg at stress). During dobutamine stress
testing, 295 patients (33%) experienced typical angina, and
ST-segment changes occurred in 293 patients (32%).
All patients had myocardial ischemia on DSE. A total of
445 patients (49%) had a peak WMSI >1.7. Patients with a
peak WMSI >1.7 had more cardiac mortality compared
with those with a peak WMSI 1.7 (30% vs 23%, respec-
tively, p ¼ 0.013). Early coronary revascularization was
performed in 222 patients (25%); a total of 113 patients
underwent PCI (51%) and 109 patients underwent CABG
(49%); a total of 3 patients (1%) underwent both PCI and
CABG. The mean interval between DSE and early revas-
cularization was 37  6 days. The remaining 683 patients
with myocardial ischemia were treated medically. Patient
groups were comparable according to age, male gender,
smoking, hypertension, diabetes mellitus and the use of
diuretics, digoxin, and platelet inhibitors. Patients who un-
derwent early revascularization more frequently had a his-
tory of cardiac disease (previous MI and heart failure) and
less frequently had a previous revascularization. Mean










Age (years  SD) 61.411.9 60.09.6 61.912.6 0.41
Men 688 (76%) 177 (80%) 511 (75%) 0.14
Smoker 300 (33%) 81 (36%) 219 (32%) 0.22
Hypertension 260 (29%) 61 (27%) 199 (29%) 0.64
Hypercholesterolemia 283 (31%) 100 (45%) 183 (27%) <0.001
Heart failure 198 (22%) 76 (34%) 122 (18%) <0.001
Diabetes mellitus 117 (13%) 28 (13%) 89 (13%) 0.87
Previous revascularization 73 (8%) 5 (2%) 68 (9%) <0.001
Previous MI 519 (57%) 166 (75%) 353 (52%) <0.001
Medications
ACE-inhibitors 303 (33%) 95 (43%) 208 (30%) <0.001
ß-blockers 381 (42%) 121 (55%) 260 (82%) <0.001
Calcium-channel blockers 294 (32%) 98 (44%) 196 (29%) <0.001
Diuretics 170 (19%) 51 (23%) 119 (17%) 0.07
Nitrates 397 (44%) 148 (67%) 249 (36%) <0.001
Echocardiographic results
Rest WMSI 1.680.60 1.760.55 1.650.61 0.01
Peak WMSI 1.790.55 1.940.52 1.740.54 <0.001
Peak WMSI >1.7 445 (49%) 138 (31%) 307 (69%) <0.001
MI ¼ myocardial infarction; WMSI ¼ wall motion score index.
Values are expressed as means  SD or numbers (%).
Figure 1. Kaplan-Meier curves for all-cause mortality according to strata of
early coronary revascularization.
Figure 2. Kaplan-Meier curves for cardiac mortality according to strata of
early coronary revascularization.
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were signiﬁcantly higher in patients who underwent early
revascularization (Table 1). This probably has contributed to
the reason for intervention.
During a median follow-up time of 10 years (range 8 to 15),
474 deaths (52%) occurred, of which were 241 (51%) due to
cardiac causes. Kaplan-Meier survival curves showed that
patients with myocardial ischemia on DSE who underwent
early revascularization had a lower risk for all-cause mortality
(event-free survival: 80% vs 65% at 5 years, 65% vs 46% at
10 years; overall p <0.001, Figure 1) and cardiac mortality
(event-free survival: 86% vs 77% at 5 years, 83% vs 66% at
10 years; overall p <0.001, Figure 2). Figures 3 and 4 dem-
onstrates the event-free survival for all-cause mortality and
cardiac mortality, respectively, according to strata of revas-
cularization and peak WMSI. In the 445 patients with mark-
edly abnormal DSE results, early revascularization wasassociated with better long-term outcomes compared with
those without early revascularization (all-cause mortality
[Figure 3] and cardiac mortality [Figure 4] both p <0.001).
Also, in the 460 patients with mild-to-moderately abnormal
DSE results, early revascularization was associated with better
long-term outcomes compared with those without early
revascularization (all-cause mortality, p <0.008, Figure 3;
cardiac mortality, p <0.001, Figure 4).
Univariable associations of long-term outcome are
presented in Tables 2 and 3. Univariable predictors of
all-cause mortality were age, male gender, hypertension,
hypercholesterolemia, history of heart failure, previous
revascularization, and rest and peak WMSI (Table 2).
Univariable predictors of cardiac mortality were age, male
gender, hypercholesterolemia, history of heart failure,
previous revascularization, previous MI, and rest and peak
WMSI (Table 3). The univariable analysis demonstrated
Figure 3. Kaplan-Meier curves for all-cause mortality according to strata of
WMSI and early coronary revascularization.
Figure 4. Kaplan-Meier curves for cardiac mortality according to strata of
WMSI and early coronary revascularization.
Table 2
Univariable and multivariable predictors of all-cause mortality
Variable Univariable Multivariable
HR 95% CI HR 95% CI
Age* 1.05 1.04-1.06 1.05 1.04-1.06
Men 1.31 1.06-1.63 1.24 0.98-1.56
Hypertension 1.33 1.10-1.61 1.46 1.18-1.79
Diabetes mellitus 0.92 0.76-1.29 1.06 0.80-1.40
Hypercholesterolemia 0.67 0.54-0.84 0.69 0.55-0.88
Smoking 1.19 0.99-1.43 1.48 1.21-1.82
Heart failure 1.46 1.18-1.81 1.30 1.02-1.66
Previous revascularization 0.44 0.25-0.77 0.42 0.23-0.76
Previous MI 1.10 0.92-1.32 0.94 0.77-1.16
Rest WMSI 1.51 1.29-1.75 1.31 0.90-1.89
Peak WMSI 1.53 1.29-1.80 1.34 0.90-2.01
Early revascularization 0.64 0.50-0.83 0.60 0.46-0.79
MI ¼ myocardial infarction; WMSI ¼ wall motion score index.
* Per unit increment.
Table 3
Univariable and multivariable predictors of cardiac mortality
Variable Univariable Multivariable
HR 95% CI HR 95% CI
Age* 1.06 1.05-1.07 1.06 1.04-1.07
Men 1.46 1.06-1.99 1.29 0.93-1.79
Hypertension 1.13 0.86-1.49 1.33 1.00-1.77
Diabetes mellitus 0.95 0.65-1.38 1.04 0.71-1.52
Hypercholesterolemia 0.62 0.45-0.84 0.65 0.47-0.90
Smoking 1.29 1.00-1.67 1.55 1.18-2.03
Heart failure 1.80 1.35-2.38 1.50 1.10-2.04
Previous revascularization 0.32 0.13-0.78 0.26 0.10-0.64
Previous MI 1.46 1.12-1.90 1.27 0.96-1.68
Rest WMSI 1.67 1.36-2.04 1.13 0.69-1.88
Peak WMSI 1.74 1.39-2.18 1.65 0.96-2.84
Early revascularization 0.54 0.38-0.78 0.49 0.34-0.72
MI ¼ myocardial infarction; WMSI ¼ wall motion score index.
* Per unit increment.
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end points of interest.
Multivariable predictors of clinical data, DSE results, and
early revascularization are listed in Tables 2 and 3. Age,
hypertension, hypercholesterolemia, smoking, history of
heart failure, and previous revascularization were associated
with both all-cause mortality (Table 2) and cardiac mortality
(Table 3). A multivariable Cox regression model revealed
that revascularization had a beneﬁcial effect on all-cause
mortality (hazard ratio 0.60, 95% conﬁdence interval 0.46
to 0.79) and cardiac mortality (hazard ratio 0.49, 95%
conﬁdence interval 0.34 to 0.72).
Discussion
In this study, the impact of early coronary revasculariza-
tion (90 days) on long-term outcomes was assessed in 905patients with myocardial ischemia. During a median follow-
up duration of 10 (range 8 to 15 years), 474 patients died, of
which 241 deaths were due to cardiac causes. Kaplan-Meier
survival curves showed that early revascularization (PCI or
CABG) after an ischemic DSE had a beneﬁcial effect on all-
cause and cardiac mortality. This beneﬁt was apparent dur-
ing the entire follow-up period,with survival curves diverging
up to 10 years. Both in patients with a mild-to-moderately
abnormal DSE (peak WMSI  1.7) and in patients with a
markedly abnormal DSE (peak WMSI > 1.7), early revas-
cularization was associated with better long-term outcomes.
When adjusting for clinical characteristics andDSE results, as
the multivariable analysis demonstrates, early revasculariza-
tion had a beneﬁcial effect on all-cause mortality (40%
reduction) and cardiacmortality (51% reduction) during long-
term follow-up.
In the present study, patients with markedly abnormal
DSE (peak WMSI > 1.7) had beneﬁt from early revascu-
larization. This is in line with previous data,13 indicating
that a certain amount of ischemia has to be present for
Coronary Artery Disease/Long-Term Prognosis After Early Revascularization 639revascularization to be beneﬁcial.14 Also, contrary to pre-
vious studies,15 patients with a mild-to-moderately
abnormal DSE (peak WMSI  1.7) who underwent early
revascularization had lower mortality compared with those
without early revascularization.
To date, CAD is the leading cause of mortality world-
wide. Patients with ischemic heart disease may be treated
with either medical therapy alone or combined with revas-
cularization (PCI or CABG). In patients with CAD, it has
been shown that left ventricle dysfunction may be reversible
after coronary revascularization.16,17 Two randomized trials
were undertaken to study the potential beneﬁt of coronary
revascularization compared with medical therapy in patients
with stable CAD. The COURAGE trial2 included 2,287
patients who had objective evidence of myocardial ischemia
and signiﬁcant coronary artery disease and studied PCI as
the revascularization procedure. Both patients in the PCI
group and those in the medical therapy group had a
preserved left ventricular ejection fraction (mean left ven-
tricular ejection fraction [LVEF] 60.8% vs 60.9%, respec-
tively). During a median follow-up of 4.6 years, the
investigators concluded that there was no beneﬁt of PCI on
death and MI. More recently, during the long-term follow-
up of up to 15 years in these patients, the investigators
did not ﬁnd a beneﬁt of survival of PCI in 1,211 patients
with stable ischemic heart disease, objective evidence of
ischemia, and signiﬁcant coronary artery disease.5 Addi-
tionally, in the Bypass Angioplasty Revascularization
Investigation 2 Diabetes (BARI-2D) trial, 2,368 diabetic
patients with evidence of ischemia, or symptoms of angina
in the presence of angiographic-deﬁned CAD, were studied
with either PCI or CABG.18 Both revascularization tech-
niques showed no beneﬁt on survival. From a clinical
perspective, both mentioned trials have important implica-
tions; patients with the characteristics of the included pa-
tients of these trials need intensive medical therapy and
lifestyle intervention. In the present study, the impact of
early coronary revascularization of patients with myocardial
ischemia on DSE was evaluated. The present study differs
from these previous trials, demonstrating that survival was
signiﬁcantly different between patients with revasculariza-
tion and those without during long-term follow-up. Jeremias
et al19 performed a meta-analysis and demonstrated that
both PCI and CABG were associated with improved sur-
vival in patients with nonacute CAD. The ﬁndings of the
present study (describing also patients with nonacute CAD)
are in line with this meta-analysis. There are several ex-
planations why early revascularization in the present patient
cohort had a beneﬁcial effect on long-term outcomes. In the
present study, we describe a high-risk group of patients who
were unable to perform an exercise test. Previous mentioned
trials enrolled low-risk patients in contrast to the present
study. Also, 57% of the 905 patients (vs 38%) had previous
myocardial infarction and 22% of the 905 patients (vs 4.7%)
had known heart failure compared with the COURAGE
trial; this also may have caused beneﬁcial effect of early
coronary revascularization in this patient cohort.
Despite major developments of PCI, advanced tech-
niques of CABG, and improvements in medication, the
optimal therapy in patients with CAD remains controver-
sial. The guidelines of the European Society of Cardiologyindicate revascularization in case of a large area of ischemia
(deﬁned as >10% of the left ventricle).3 The American
guidelines recommend CABG in preference to PCI to
improve survival in patients with multivessel CAD.20 In
both guidelines, special considerations are made for diabetic
patients; revascularization should be considered for diabetic
patients whose symptoms compromise their quality of life.
Also, in diabetic patients with stable CAD and an accept-
able surgical risk, CABG is recommended over PCI. The
present study included 117 patients (13%) with diabetes
mellitus. Clearly, multiple factors inﬂuence the decision to
perform coronary revascularization, including symptoms,
presence of myocardial ischemia, coronary anatomy, and
comorbid conditions. Moreover, daily clinical practice re-
quires the need of balancing between invasive CABG and
less invasive PCI. The International Study of Comparative
Health Effectiveness with Medical and Invasive Ap-
proaches (ISCHEMIA) trial (including >8,000 patients
with at least moderate ischemia on an ischemia test) aims to
demonstrate whether patients will beneﬁt from a treatment
of cardiac catheterization, revascularization, and medical
therapy or a treatment of medical therapy alone with cardiac
catheterization specially for those who fail medical
therapy.21
Patients with stable CAD and myocardial ischemia who
undergo no or delayed revascularization are at increased risk
of adverse events. This may have several reasons. First,
chronic myocardial ischemia may result in hibernating or
scarred myocardium and an impairment of LV function.17
Second, patients with myocardial ischemia are at increased
risk of developing ventricular arrhythmias, especially those
with a severely impaired LV function.22 Third, natural
progression of CAD may result in adverse events, including
myocardial infarction.
Patients in the present study were unable to perform
exercise testing because of comorbid conditions. DSE may
be a valuable alternative method for the evaluation of
myocardial ischemia in these patients. DSE has been
established as a relatively safe stress technique.23 Noncar-
diac side effects (nausea, headache, chills, urgency, and
anxiety) are usually well tolerated, without the need for test
termination. The most common cardiovascular side effects
are angina, hypotension, and cardiac arrhythmias.23 Life-
threatening complications are rare, and in patients at
increased risk for these complications (those with impaired
LV function and/or a previous infarction), close monitoring
is required also during the recovery phase, and any possible
cardiovascular or neurologic symptoms should be addressed
immediately. The risk-beneﬁt ratio of DSE should always
be evaluated carefully.
This study has some limitations. First, the decision to
revascularize was made on clinical grounds. The decision to
perform early coronary revascularization may have been
inﬂuenced by multiple factors like age, life expectancy, and
comorbid conditions. These factors may also have inﬂu-
enced long-term outcomes. Second, at the time of data
collection, contrast-enhanced stress echocardiography was
not routinely performed. The use of an ultrasound contrast
agent could further increase the accuracy and simultaneous
evaluation of myocardial function and perfusion.24 Medi-
cations that reduce mortality in patients with CAD include
640 The American Journal of Cardiology (www.ajconline.org)b blockers, angiotensin-converting enzyme inhibitors, and
statins. At the time of data collection, however, these
medications were underused, probably because the beneﬁ-
cial effect of these medications was not yet fully under-
stood.25 Finally, at the time of data collection, LVEF was
not routinely performed in our center. Information about
LVEF could have improved the present analysis.
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